GSK, Cytokinetics to terminate cancer drug R&D partnership

12/10/2009 | American City Business Journals

GlaxoSmithKline will transfer to Cytokinetics all rights to GSK-923295, a drug candidate for solid tumors, by the end of February after the two drugmakers agreed to terminate their eight-year research partnership. Cytokinetics said it plans to license GSK-923295 as well as SB-743921 and SB-715992, two other cancer drug candidates that GSK turned over in 2008.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC